Biotechnology
For the first time in clinical oncology history, daraxonrasib has extended median overall survival past one year in previously treated metastatic pancreatic cancer—a breakthrough that rewrites what medicine can offer in one of oncology's most resistant diseases.
Biotechnology
At ASCO 2026, two competing KIT inhibitor programs delivered data that together signal the end of a twenty-year therapeutic standstill in gastrointestinal stromal tumors.
Pharmaceuticals
Pfizer's $10.5 billion deal with China's Innovent Biologics signals a major strategic shift in how Western pharma is leveraging Chinese biotech innovation in oncology.
Biotechnology
GSK's bepirovirsen achieves functional cure in nearly one in five hepatitis B patients—a breakthrough after sixty years of managing the disease without curing it.
Biotechnology
Eli Lilly is making a $4 billion commitment to rebuild its infectious disease portfolio from scratch, acquiring three vaccine developers and signaling a strategic pivot away from its GLP-1 dominance.
Biotechnology
Eli Lilly's VERVE-102 data show a single infusion can permanently reduce LDL cholesterol by 50-70%, potentially transforming cardiovascular disease management and solving the adherence problem that has plagued statins for decades.
Pharmaceuticals
The FDA's accelerated approval of Gilead's Hepcludex marks the first-ever US treatment for hepatitis delta virus, ending decades of therapeutic neglect for one of the most severe forms of viral hepatitis.
Biotechnology
Merck and Kelun's sacituzumab tirumotecan combined with pembrolizumab shows a 65% improvement in progression-free survival versus Keytruda monotherapy in first-line NSCLC, marking a potential paradigm shift in lung cancer treatment.
Biotechnology
The WHO has declared the Bundibugyo Ebola outbreak a global health emergency. With no approved treatments, the US government has turned to a small San Diego biotech and its experimental antibody MBP134. The story reveals a structural gap in how the world prepares for infectious disease.
Most people at this point have heard of Ozempic. Far fewer have heard of the patients it does not help. For a meaningful subset of obese patients, GLP-1 drugs simply do not work, because the appetite circuit in their brain is broken in a way GLP-1 mechanisms cannot
Pharmaceuticals
AstraZeneca's Baxfendy (baxdrostat) is the first aldosterone synthase inhibitor approved by the FDA, offering a fundamentally new approach to treating resistant hypertension in the 23 million Americans whose blood pressure remains uncontrolled despite multiple medications.
Biotechnology
Three competing technologies—from Sanofi, Wave Life Sciences, and Beam Therapeutics—are finally challenging Alpha-1 Antitrypsin Deficiency after four decades of limited treatment options.